Literature DB >> 18549877

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Takeaki Ishizawa1, Kiyoshi Hasegawa, Taku Aoki, Michiro Takahashi, Yosuke Inoue, Keiji Sano, Hiroshi Imamura, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi.   

Abstract

BACKGROUND & AIMS: The surgical indications for multiple hepatocellular carcinomas (HCCs) and for HCC with portal hypertension (PHT) remain controversial.
METHODS: We reviewed 434 patients who had undergone an initial resection for HCC and divided them into a multiple (n = 126) or single (n = 308) group according to the number of tumors. We also classified 386 of the patients into a PHT group (n = 136) and a no-PHT (n = 250) group according to whether they had PHT (defined by the presence of esophageal varices or a platelet count of <100,000/microL in association with splenomegaly).
RESULTS: Among Child-Pugh class A patients, the overall survival rates in the multiple group were 58% at 5 years, and 56% in the PHT group, which were lower than those in the single group (68%, P = .035) and the no-PHT group (71%, P = .008). Among Child-Pugh class B patients with multiple HCCs, the 5-year overall survival rate was 19%. Multivariate analyses revealed that the presence of multiple tumors was an independent risk factor for postoperative recurrence (relative risk, 1.64; 95% confidence interval, 1.23-2.18; P = .001). A second resection resulted in satisfactory overall survival after the diagnosis of recurrence in the multiple (73% at 3 years) or PHT (73%) groups, as well as in the single (79%) or no PHT (81%) groups.
CONCLUSIONS: Resection can provide survival benefits even for patients with multiple tumors in a background of Child-Pugh class A cirrhosis, as well as in those with PHT.

Entities:  

Mesh:

Year:  2008        PMID: 18549877     DOI: 10.1053/j.gastro.2008.02.091

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  229 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma.

Authors:  Young-Joo Jin; Young-Hwa Chung; Jeong A Kim; Won Hyung Park; Danbi Lee; Dong Dae Seo; Soo Hyung Ryu; Myoung Kuk Jang; Eunsil Yu; Young Joo Lee
Journal:  Dig Dis Sci       Date:  2012-07-10       Impact factor: 3.199

Review 3.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

4.  Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma.

Authors:  Ling Deng; Chun Yang; Le-Qun Li; Jian-Hong Zhong
Journal:  J Gastrointest Surg       Date:  2015-10-13       Impact factor: 3.452

5.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

6.  Role of liver resection in the management of multinodular hepatocellular carcinoma.

Authors:  Osman Abbasoglu
Journal:  World J Hepatol       Date:  2015-09-18

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

8.  Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma.

Authors:  Bao-Hong Yuan; Wei-Ping Yuan; Ru-Hong Li; Bang-De Xiang; Wen Feng Gong; Le-Qun Li; Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-09-17

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma.

Authors:  Ru-Ting Xie; Xian-Ling Cong; Xiao-Ming Zhong; Ping Luo; Hui-Qiong Yang; Gai-Xia Lu; Pei Luo; Zheng-Yan Chang; Ran Sun; Ting-Miao Wu; Zhong-Wei Lv; Da Fu; Yu-Shui Ma
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.